2020-06-25T15:26:41-05:00 2019-06-30 ERNST & YOUNG US LLP 4365 EXECUTIVE DRIVE STE 1600 SAN DIEGO CA 92121 990 2018-07-01 510197108 SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE % LOUIS COFFMAN SANF 8586463100 10901 NORTH TORREY PINES ROAD LA JOLLA CA 92037 LOUIS COFFMAN CAO & CFO 8586463100 2020-06-17 true JOCELYNE MILLER P00634378 8585357200 99.132.79.23 33008120201775000003 2020-06-25 P DE6C2DF5A9AF955A85F13E615B2394729CA127AA 36F6D57CE89615FC2EEC8448977178FD35DAD353 2018 2020-09-23 17:36:50Z KRISTIINA VUORI 10901 NORTH TORREY PINES ROAD LA JOLLA CA 92037 267516050 false X WWW.SBPDISCOVERY.ORG X 1976 CA SEE SCHEDULE O 17 16 911 19 1353769 0 113630164 108300329 1300446 799803 6744651 11593574 3651490 2262753 125326751 122956459 0 0 0 0 76269756 65811734 0 0 1277432 67249608 120469124 143519364 186280858 -18192613 -63324399 430760547 338796799 149095244 123189379 281665303 215607420 X SEE SCHEDULE O false false 100125314 0 1018511 SEE SCHEDULE O 100125314 true true false true false false false false false true true true false false false true true false false true true false false false true false false false false true true false false false false false false false false false false false false false false false true true false false false true 212 0 true 911 true true true false false false false true true false false false false false false X 17 16 false false false false false false false true true false false true true true true true true true true false AL AK AR CA CO CT DC FL GA IL KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X LOUIS COFFMAN 8586463100 10901 N Torrey Pines RD La Jolla CA 92037 KRISTIINA VUORI MD PHD PRESIDENT 50.0 0.0 X X 1010709 0 345320 DOUGLAS OBENSHAIN TRUSTEE 1.0 0.0 X 0 0 0 DAVID DOWN TRUSTEE 1.0 0.0 X 0 0 0 WILLIAM GERHART VICE CHAIRMAN 1.0 0.0 X X 0 0 0 ALAN GLEICHER TRUSTEE (PART YEAR) 1.0 0.0 X 0 0 0 JEANNE HERBERGER TRUSTEE 1.0 0.0 X 0 0 0 STUART TANZ TRUSTEE 1.0 0.0 X 0 0 0 JAMES JARDON TRUSTEE 1.0 0.0 X 0 0 0 DONALD ROSENBERG TRUSTEE (PART YEAR) 1.0 0.0 X 0 0 0 JAMES MYERS TRUSTEE 1.0 0.0 X 0 0 0 KAZUMI SHIOSAKI TRUSTEE 1.0 0.0 X 0 0 0 PETER SEIDLER TRUSTEE 1.0 0.0 X 0 0 0 ANNA BARKER TRUSTEE 1.0 0.0 X 0 0 0 DANIEL EPSTEIN TRUSTEE 1.0 0.0 X 0 0 0 HENRY NORDOFF TRUSTEE 1.0 0.0 X 0 0 0 JAMES BLAIR CHAIR 1.0 0.0 X X 0 0 0 WILLIAM ROPER TRUSTEE 1.0 0.0 X 0 0 0 MATTHEW BROWNE TRUSTEE 1.0 0.0 X 0 0 0 DAVID SZEKERED TRUSTEE 1.0 0.0 X 0 0 0 KNOX BELL CORPORATE SECRETARY 2.0 0.0 X 0 0 0 GARY CHESSUM CFO (THRU 7/31/2018) 50.0 0.0 X 218557 0 30716 LOUIS COFFMAN CAO & CFO 50.0 0.0 X 207752 0 23657 GARTH POWIS PHD CENTER DIRECTOR 50.0 0.0 X 504465 0 47628 CARL WARE PHD CENTER DIRECTOR, IIDC 50.0 0.0 X 404789 0 47395 MICHAEL JACKSON PHD DRUG DISCOVERY & DEV, SR VP 50.0 0.0 X 439813 0 58021 RANDAL KAUFMAN PHD PROGRAM DIRECTOR 50.0 0.0 X 360737 0 58331 JORGE MOSCAT PHD PROGRAM DIRECTOR 50.0 0.0 X 350276 0 57743 PERRY NISEN FORMER CEO 50.0 0.0 X 780458 0 0 4277556 0 668811 144 true true false DLA Piper LLP PO Box 64029 Baltimore MD 21264 Legal Services 647033 Superion LLC 12709 Collection Center Dr Chicago IL 60693 Software Development 461826 DELOITTE TOUCHE LLP 655 WEST BROADWAY SUITE 400 SAN DIEGO CA 92101 AUDIT SERVICES 287648 Wilson Sonsini Goodrich PO Box 742866 LOS ANGELES CA 90074 Legal Services 249527 Stealth Partner Group 18940 NOrth Pima Road Suite 210 Scottsdale AZ 85255 Admin Services 203673 7 828901 68140747 39330681 4080 108300329 SHARED SERVICES REVENUE 541990 799803 799803 0 0 799803 4957099 4957099 0 971229 971229 13960 13960 0 13960 13960 150841666 144205191 6636475 6636475 6636475 59487 828900 354400 -294913 -294913 0 0 0 0 0 0 RESEARCH 541700 1353769 0 1353769 0 OTHER RESEARCH SUPPORT 541990 28816 28816 0 0 SALE OF REAGENTS 541990 28256 28256 0 0 161636 161636 0 1572477 122956459 1018511 1353769 12283850 0 0 0 0 0 0 0 0 1240167 154502 1085665 0 780458 0 780458 0 49409343 39978741 8753432 677170 3325036 2636505 632128 56403 8054800 6589802 1401993 63005 3001930 2303943 655231 42756 1084184 417876 610208 56100 643181 54570 588611 0 375420 0 375420 0 1200 0 1200 0 0 0 697100 0 697100 0 818904 634526 172704 11674 23974 0 108 23866 6366860 5663217 654581 49062 1459944 1107654 314321 37969 0 0 0 0 12201330 10856400 1273424 71506 425568 366755 51894 6919 0 0 0 0 1046410 805009 202674 38727 1919481 1747687 158933 12861 0 0 0 0 8968041 8121441 794225 52375 0 0 0 0 CONTRIBUTED ASSETS 65411144 0 65411144 0 RESEARCH SUPPLIES & SVCS 10410668 10410668 0 0 SCIENTIFIC COLLABORATIONS 8089399 8089399 0 0 Bad Debt 222285 0 222285 0 304031 186619 40373 77039 186280858 100125314 84878112 1277432 0 5792608 8780651 13539386 2469 9531085 11771097 345952 470995 911111 0 0 0 693912 377300 145372 45516 6819615 7961896 162402217 105290986 125185822 57111231 247437682 218451769 18047415 33823875 0 0 0 0 2310587 0 430760547 338796799 16125390 15973902 0 0 75065356 52727813 57904498 54487664 0 0 0 0 0 0 0 0 0 0 149095244 123189379 X 199720438 184566051 67889349 16991325 14055516 14050044 281665303 215607420 430760547 338796799 -63324399 -2733484 0 0 0 X false true X true true true X 240798040 112703072 121777889 113630164 108300329 697209494 0 0 240798040 112703072 121777889 113630164 108300329 697209494 63750592 633458902 6992391 5532193 6303751 5346565 5942288 30117188 160548 52137 281883 48551 0 543119 0 0 727869801 8676314 0.87029 0.85620 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false 0 false 0 false 0 false 0 false 0 false 0 true 1200 1200 false SCHEDULE C, PART II-B, LINE 1I Dues to a research and biomedical organization, a portion of which is considered lobbying. 29799743 4000 1337873 1327075 29814541 28681314 502000 1841686 1225257 29799743 25987641 530336 3395420 1232083 28681314 26693919 510067 -3125 1213220 25987641 26870514 920000 36749 1133344 26693919 0.32000 0.47000 0.21000 false false 0 12758161 12758161 0 86906542 54330620 32575922 0 62183549 50960366 11223183 0 553965 553965 57111231 PRIVATE EQUITY LPS 1769079 F TOTAL RETURN HEDGE FUNDS 19525233 F SELECT EQUITY FUNDS 12529563 F 33823875 0 0 X 119524000 -2733484 -2733484 122257484 697100 1875 698975 122956459 185582000 0 0 185582000 697100 1758 698858 186280858 SCHEDULE D, PART V, LINE 4 INTENDED USES OF THE ORGANIZATION'S ENDOWMENT FUNDS THE INSTITUTE'S ENDOWMENT FUNDS ARE ESTABLISHED FOR VARIOUS PURPOSES: SCIENTIFIC RESEARCH, CEO CHAIR, PRESIDENTIAL CHAIR, CANCER AND NEUROSCIENCE LEADERSHIP CHAIRS, AND UNRESTRICTED AS TO INCOME. SCHEDULE D, PART X, LINE 2 FIN 48 (ASC 740) FOOTNOTE THE INSTITUTE HAS NO MATERIAL DEFERRED TAX ASSETS OR DEFERRED TAX LIABILITIES RECORDED AS OF JUNE 30, 2019 AND 2018. THE INSTITUTE DID NOT RECOGNIZE A CHANGE IN LIABILITY FOR UNRECOGNIZED TAX BENEFITS (THE DIFFERENCE BETWEEN A TAX POSITION TAKEN, OR EXPECTED TO BE TAKEN, IN A TAX RETURN AND THE BENEFIT RECOGNIZED AND MEASURED IN THE FINANCIAL STATEMENTS). THERE WERE NO LIABILITIES FOR UNRECOGNIZED TAX BENEFITS AT JUNE 30, 2019 AND 2018. SCHEDULE D, PART XI, LINE 4B ROUNDING - 1,875 SCHEDULE D, PART XII, LINE 4B ROUNDING - 1,758 Europe (Including Iceland and Greenland) 40 Program Services See Part V 122863 East Asia and the Pacific 2 Program Services See Part V 24099 North America 1 Program Services See Part V 381 South Asia Program Services See Part V 6377 Middle East and North Africa Program Services See Part V 3948 Russia and the Newly Independent States Program Services See Part V 5417 South America Program Services See Part V 2682 Central America and the Caribbean Investments 17584656 43 43 17750423 17750423 true false true true true false SCHEDULE F, PART I, LINE 3 PROGRAM SERVICE ACTIVITIES SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE DOES NOT MAINTAIN ONGOING OPERATIONS IN FOREIGN JURISDICTIONS. HOWEVER, THE INSTITUTE'S SCIENTISTS DO TRAVEL TO VARIOUS SCIENTIFIC CONFERENCES IN OTHER COUNTRIES TO SHARE THE INSTITUTE'S SCIENTIFIC DISCOVERIES AND TO LEARN FROM OTHER SCIENTISTS ACROSS THE WORLD. SCHEDULE F, PART I, LINE 3, COLUMN E TYPE OF SERVICE SPECIFIC PROGRAM SERVICE ACTIVITY IN ALL REGIONS IS AGENTS ATTENDING AND/OR SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS. SCHEDULE F, PART I, LINE 3, COLUMN F ACCOUNTING METHOD THE ACCRUAL METHOD OF ACCOUNTING WAS USED TO DETERMINE THE AMOUNTS IN PART I, LINE 3, COLUMN F. ED GILLENWATERS CONSULTING false BLAIR BLUM PARTNERS CONSULTING false GALA 645853 621853 24000 65071 49648 71726 BRING IT 242535 207048 35487 7136 63392 6580 90847 0 888388 828901 59487 7136 128463 56228 162573 354400 -294913 X X true true X X X X X X true true false false false false false true false KRISTIINA VUORI MD PHD PRESIDENT 758611 0 250000 0 2098 0 327500 0 17820 0 1356029 0 0 0 GARY CHESSUM CFO (THRU 7/31/2018) 217139 0 0 0 1418 0 16322 0 14394 0 249273 0 0 0 GARTH POWIS PHD CENTER DIRECTOR 448246 0 50000 0 6219 0 27500 0 20128 0 552093 0 0 0 CARL WARE PHD CENTER DIRECTOR, IIDC 380717 0 18902 0 5170 0 27500 0 19895 0 452184 0 0 0 MICHAEL JACKSON PHD DRUG DISCOVERY & DEV, SR VP 397195 0 39395 0 3223 0 27500 0 30521 0 497834 0 0 0 PERRY NISEN FORMER CEO 0 0 0 0 780458 0 0 0 0 0 780458 0 0 0 LOUIS COFFMAN CAO & CFO 205559 0 0 0 2193 0 14063 0 9594 0 231409 0 0 0 RANDAL KAUFMAN PHD PROGRAM DIRECTOR 355774 0 0 0 4963 0 27500 0 30831 0 419068 0 0 0 JORGE MOSCAT PHD PROGRAM DIRECTOR 345940 0 0 0 4336 0 27500 0 30243 0 408019 0 0 0 FORM 990, SCHEDULE J, PART I, LINE 1A FIRST CLASS TRAVEL FIRST CLASS TRAVEL IS GENERALLY NOT PERMITTED, EXCEPT UNDER VERY LIMITED AND RARE CIRCUMSTANCES AND CONDITIONS, SUCH AS A MEDICAL CONDITION REQUIREMENT AND URGENT CIRCUMSTANCES. THIS WAS NOT TREATED AS TAXABLE COMPENSATION. HEALTH OR SOCIAL CLUB DUES HEALTH OR SOCIAL CLUB DUES ARE NEGOTIATED IN THE HIRING PROCESS FOR CERTAIN EMPLOYEES. THE AMOUNTS WERE TREATED AS TAXABLE COMPENSATION. FORM 990, SCHEDULE J, PART I, LINE 4A DURING THE YEAR THE ORGANIZATION PAID SEVERANCE UNDER A CONFIDENTIAL SEVERANCE AGREEMENT TO ONE INDIVIDUAL. FORM 990, SCHEDULE J, PART I, LINE 4B SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN THE PARTICIPANT OF THE 457(F) DEFERRED COMPENSATION PLAN IS KRISTIINA VUORI. VESTING OCCURS THE EARLIEST OF 04/01/20, OR INVOLUNTARY TERMINATION WITHOUT CAUSE, OR PARTICIPANT'S RESIGNATION FOR GOOD CAUSE, OR THE DATE OF TERMINATION OF THE PLAN. DISTRIBUTION IS A ONE-TIME LUMP SUM PAYMENT UPON VESTING OF 100% OF THE VALUE OF THE PARTICIPANT'S INVESTMENT (COMPRISED OF INSTITUTE CONTRIBUTIONS TO THE CORPUS PLUS ANY INVESTMENT GAINS OR LOSSES THEREON). FORM 990, SCHEDULE J, PART I, LINE 7 NON-FIXED PAYMENTS SOME SENIOR EXECUTIVES HAVE EMPLOYMENT AGREEMENTS STIPULATING A BONUS WILL BE PAID TO THEM PROVIDED CERTAIN GOALS OR ACCOMPLISHMENTS ARE ACHIEVED. A COUNTY OF SAN DIEGO 956000934 79742YAQ5 2015-11-12 61963256 SEE PART VI false false false A 0 11658870 61963256 0 0 50015000 289386 0 0 0 0 0 2015 true false true true A false true true true true true 0.01590 0.01590 false false false true A false true false false true false 0 false 0 false true A true SCHEDULE K, PART I, ROW A, COLUMN (F) REFINANCE 2006 AND 2012 BONDS WITH ISSUE DATES OF 02/01/2006 AND 11/15/2012, RESPECTIVELY. SCHEDULE K, PART I, ROW A FOR THE BOND ISSUES LISTED IN PART I, THE ALTERNATIVE PERIOD USED FOR THE REPORTING REQUIREMENTS IN THIS SECTION IS THE TWELVE MONTHS ENDED DECEMBER 31, 2018. FORM 990, PART I, LINE 1 & PART III, LINE 1 ORGANIZATIONS MISSION SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE CONDUCTS WORLD-CLASS, COLLABORATIVE RESEARCH DEDICATED TO FINDING CURES FOR HUMAN DISEASE, IMPROVING THE QUALITY OF LIFE, AND THUS CREATING A LEGACY FOR ITS EMPLOYEES, PARTNERS, DONORS, AND COMMUNITY. FORM 990, PART III, LINE 4 PROGRAM SERVICE ACCOMPLISHMENTS SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (SBP) IS AN INDEPENDENT NONPROFIT MEDICAL RESEARCH ORGANIZATION THAT DEDICATED TO UNCOVERING THE ORIGINS OF DISEASE AND LAUNCHING BOLD NEW STRATEGIES LAYING THE FOUNDATION FOR CURES. OUR INSTITUTE HAS DEEP EXPERTISE IN FUNDAMENTAL BIOLOGY AND ONE OF THE MOST COMPREHENSIVE DRUG DISCOVERY CENTERS IN THE NONPROFIT WORLD. CANCER CONQUERING CANCER'S INFAMOUS KRAS MUTATION. KRAS IS ONE OF THE MOST CHALLENGING TARGETS IN CANCER. DESPITE ITS DISCOVERY MORE THAN 60 YEARS AGO, RESEARCHERS STILL STRUGGLE TO BLOCK THE CANCER-CAUSING PROTEIN - EARNING ITS REPUTATION AS "UNDRUGGABLE." GARTH POWIS, D.PHIL., LED RESEARCH IDENTIFYING A PROMISING COMPOUND CALLED PHT-7.3 THAT SHRINKS KRAS TUMORS IN MICE. NEARLY 25% OF ALL HUMAN CANCERS ARE KRAS-POSITIVE. POTENTIAL TARGETED TREATMENT FOR ACUTE MYELOID LEUKEMIA. ACUTE MYELOID LEUKEMIA IS A DEADLY BLOOD CANCER WITH LIMITED TREATMENT OPTIONS. FOR PATIENTS OVER 20 YEARS OLD, THE 5-YEAR SURVIVAL IS APPROXIMATELY 25%. ANI DESHPANDE, PH.D., FOUND THAT BLOCKING A PROTEIN CALLED BMI1 WITH A SPECIFIC COMPOUND PROLONGED SURVIVAL OF MOUSE MODELS OF THE DISEASE. THE COMPOUND IS IN CLINICAL DEVELOPMENT FOR ADVANCED SOLID TUMORS BY PTC THERAPEUTICS. PANCREATIC TUMORS SCAVENGE TO SURVIVE. RAPIDLY GROWING PANCREATIC TUMORS GATHER NUTRIENTS THROUGH A SUPPLY ROUTE CALLED MICROPINOCYTOSIS, WHEREBY SMALL PARTICLES ARE ENGULFED VIA THE CELL MEMBRANE. COSIMO COMMISSO, PH.D., DISCOVERED THAT SOME TUMORS HAVE NATURALLY HIGH LEVELS OF MICROPINOCYTOSIS, WHILE OTHERS CAN DIAL UP OR DOWN NUTRIENT SCAVENGING AS NEEDED DURING DISEASE PROGRESSION. THE RESEARCH ALSO IDENTIFIED MOLECULAR REGULATORS OF THE PROCESS WHICH MAY ULTIMATELY LEAD TO PERSONALIZED TREATMENTS TO STARVE TUMORS. STUDY OFFERS NEW APPROACH TO STARVING TUMORS. FOR YEARS, SCIENTISTS HAVE TRIED TO HALT CANCER BY BLOCKING THE NUTRIENTS THAT TUMORS NEED TO GROW. THESE STRATEGIES HAVE OFTEN FAILED BECAUSE CANCER CELLS ARE CRAFTY-THEY HAVE BACKUP PLANS TO GATHER THE FOOD AND OXYGEN THAT THEY NEED TO SURVIVE. BROOKE EMERLING, PH.D., LED RESEARCH REVEALING AN ALTERNATIVE METABOLIC PATHWAY USED BY CANCER CELLS THAT MAY BE TARGETED TO STARVE TUMORS. TARGETING LONG-SOUGHT CANCER RECEPTOR BECOMES CRYSTAL CLEAR. SCIENTISTS HAVE LONG SOUGHT TO TARGET A RECEPTOR CALLED EPHA2 BECAUSE OF ITS KNOWN ROLE IN CANCER AND OTHER DISORDERS INCLUDING INFLAMMATORY CONDITIONS, NEUROLOGICAL DISORDERS AND INFECTIOUS DISEASES. ELENA PASQUALE, PH.D., PUBLISHED RESEARCH ON THE STRUCTURE OF THE RECEPTOR AND ENGINEERED POWERFUL COMPOUNDS THAT ACTIVATE OR INACTIVATE IT, PAVING THE WAY FOR NEW THERAPIES. HOW PROSTATE CANCER BECOMES TREATMENT RESISTANT. SOME MEN WHO RECEIVE ANTI-ANDROGEN THERAPY FOR PROSTATE CANCER DEVELOP NEUROENDOCRINE PROSTATE CANCER (NEPC)-A DEADLY SUBTYPE WITH NO EFFECTIVE TREATMENT. MARIA DIAZ-MECO, PH.D., LED A STUDY DESCRIBING THE MOLECULAR "SWITCH" THAT DRIVES THIS TRANSFORMATION. THE FINDINGS REVEAL THAT AN FDA-APPROVED DRUG HOLDS POTENTIAL AS AN NEPC TREATMENT, AND NEW THERAPEUTIC AVENUES THAT COULD PREVENT THE TRANSFORMATION FROM OCCURRING. LOSS OF GENES DRIVES DEADLY COLORECTAL CANCERS. SOME COLON POLYPS PROGRESS TO A TREATMENT-RESISTANT CANCER CALLED SERRATED COLORECTAL CANCER. MARIA DIAZ-MECO, PH.D. AND JORGE MOSCAT, PH.D., LED RESEARCH THAT REVEALED TWO GENETIC MARKERS THAT CLEARLY IDENTIFY THE SERRATED SUBGROUP OF COLORECTAL CANCER TUMORS. THE STUDY, PERFORMED IN MICE, ALSO IDENTIFIED TWO DRUGS THAT WERE SUCCESSFUL IN REDUCING THE NUMBER AND SIZE OF THESE TUMORS. THE FINDINGS SUGGEST A POTENTIAL BIOMARKER AND PROMISING TREATMENT APPROACH FOR THIS OFTEN-DEADLY CANCER. DISORDERS OF METABOLISM RESEARCH TO RESTORE INSULIN PRODUCTION IN DIABETES. IF YOU HAVE DIABETES, THERE IS A STRONG CHANCE YOU ARE EITHER ON INSULIN THERAPY NOW OR WILL BE IN THE FUTURE. A NEW STUDY BY FRED LEVINE, M.D., PH.D., FOUND THAT UNDER THE RIGHT CIRCUMSTANCES, INSULIN-MAKING "BETA" CELLS COULD BE REGENERATED IN MICE USING THREE DRUGS. ALTHOUGH MORE RESEARCH IS NEEDED, THE FINDINGS COULD ONE DAY FREE MILLIONS OF PATIENTS FROM DAILY DOSES OF INSULIN. MANNOSE'S UNEXPECTED EFFECTS ON THE MICROBIOME AND WEIGHT GAIN. HUDSON FREEZE, PH.D., PUBLISHED RESEARCH DESCRIBING HOW MICE FED A FATTY DIET AND MANNOSE (A SUGAR) WERE PROTECTED FROM WEIGHT GAIN AND WERE MORE FIT. THE EFFECTS WERE ATTRIBUTED TO CHANGES IN THE GUT MICROBIOME BUT WERE ONLY ATTAINED WHEN THE MICE RECEIVING MANNOSE WERE YOUNG, SUGGESTING THE GUT MICROBIOME IS VERY DYNAMIC EARLY IN LIFE. THE RESEARCH CONFIRMS THE IMPORTANT ROLE OF THE GUT MICROBIOME IN METABOLISM AND MAY LEAD TO NEW THERAPIES FOR TREATING OBESITY. IMMUNITY HARNESSING NANOPARTICLES TO FIGHT DRUG-RESISTANT INFECTIONS. ERKKI RUOSLAHTI, M.D., PH.D., CO-AUTHORED A STUDY THAT DESCRIBES THE FIRST EXAMPLE OF AN EFFECTIVE GENE THERAPY APPROACH TO FIGHT LETHAL BACTERIAL INFECTIONS. THE METHOD USES NANOPARTICLES TO TARGET SPECIFIC IMMUNE CELLS TO BOLSTER THE IMMUNE SYSTEM. THE TECHNIQUE WAS SUCCESSFULLY USED AGAINST A LETHAL BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS PNEUMONIA IN MICE. NEW INSIGHTS INTO T CELL SURVIVAL. A HEALTHY POOL OF CIRCULATING T CELLS IS ESSENTIAL TO KILL PATHOGENS, MAKE ANTIBODIES, SHUT DOWN THE IMMUNE SYSTEM TO PREVENT UNCONTROLLED INFLAMMATION AND AUTOIMMUNE DISORDERS-AND EVEN FIGHT CANCER. A NEW STUDY BY MAXIMILIANO D'ANGELO, PH.D., IDENTIFIED A NUCLEAR PORE PROTEIN THAT IS CRITICAL FOR THE SURVIVAL OF CIRCULATING T CELLS, PAVING THE WAY FOR POTENTIAL ADVANCES IN IMMUNOTHERAPY. GUT MICROBIOME DIRECTS THE IMMUNE SYSTEM TO FIGHT CANCER. IMMUNOTHERAPY HAS BEEN A SIGNIFICANT BREAKTHROUGH IN CANCER TREATMENT-BUT IT DOESN'T WORK FOR EVERYONE. ZE'EV RONAI, PH.D., LED A WORLDWIDE COLLABORATION DEMONSTRATING A CAUSAL LINK BETWEEN THE GUT MICROBIOME AND THE IMMUNE SYSTEM'S ABILITY TO FIGHT CANCER. THE STUDY IDENTIFIED A COCKTAIL OF 11 BACTERIAL STRAINS THAT ACTIVATE THE IMMUNE SYSTEM AND SLOW THE GROWTH OF MELANOMA IN MICE. THE FINDINGS OPEN NEW RESEARCH AVENUES TO TURN ON ANTI-TUMOR IMMUNITY IN PATIENTS WITH CANCER. PATH TO DEADLY SEPSIS VARIES BY BACTERIAL INFECTION. SEPSIS IS A POTENTIALLY DEADLY CONDITION THAT OCCURS WHEN THE BODY REACTS TO AN INFECTION IN THE BLOODSTREAM. JAMEY MARTH, PH.D., LED RESEARCH SHOWING HOW RESPONSES DURING SEPSIS CAN VARY BASED ON THE PATHOGEN. SEPSIS CAUSED BY SALMONELLA OR E. COLI (GRAM-NEGATIVE BACTERIA) ACTIVATED THE HOST INFLAMMATORY RESPONSE, REDUCING THE LIKELIHOOD OF SURVIVAL. THE FINDINGS SUGGEST THAT BOOSTING ANTI-INFLAMMATORY ENZYMES MAY BE A FIRST-LINE THERAPEUTIC DEFENSE AGAINST THESE TYPES OF INFECTIONS. NEUROSCIENCE ANTIMICROBIAL PROTEIN IMPLICATED IN PARKINSON'S DISEASE. WANDA REYNOLDS, PH.D., MADE A DISCOVERY SHOWING THAT AN IMMUNE SYSTEM PROTEIN THAT USUALLY PROTECTS OUR BODIES FROM PATHOGENS IS ABNORMALLY PRODUCED DURING PARKINSON'S DISEASE. THE DISCOVERY INDICATES THAT DEVELOPING A DRUG THAT BLOCKS THE PROTEIN, CALLED MYELOPEROXIDASE, MAY HELP PEOPLE WITH PARKINSON'S DISEASE. ALS RESEARCH REVEALS NEW AVENUE FOR THERAPEUTICS DISCOVERY. AMYOTROPHIC LATERAL SCLEROSIS (ALS, OFTEN REFERRED TO AS LOU GEHRIG'S DISEASE) IS CAUSED BY LOSS OF MOTOR NEURONS IN THE BRAIN AND SPINAL CORD, WHICH LEADS TO GRADUAL MUSCLE DECLINE. HUAXI XU, PH.D., REVEALED THAT A PROTEIN CALLED MEMBRALIN PLAYS A KEY ROLE IN ALS AND IDENTIFIED A MEMBRALIN-BOOSTING GENE THERAPY THAT EXTENDED THE LIFE OF MICE WITH ALS-LIKE SYMPTOMS. ADDITIONAL RESEARCH AND CLINICAL TRIALS MAY ADVANCE THE APPROACH TO TREAT PATIENTS WITH THE DISEASE. MUSCLE DISCOVERY MAY OPEN NEW TREATMENT PATHS FOR ALS. LORENZO PURI, M.D., LED RESEARCH SHOWING HOW THE CELLS NEEDED TO HEAL OUR MUSCLES-CALLED FIBRO-ADIPOGENIC PROGENITORS (FAPS)-HAVE A DARK SIDE. IN NEURODEGENERATIVE DISEASES, SUCH AS ALS (LOU GEHRIG'S DISEASE), FAPS SIGNAL THE IMMUNE SYSTEM TO GO INTO OVERDRIVE, CAUSING MUSCLE WASTING AND SCARRING. BLOCKING FAP'S SIGNAL IN MOUSE MODELS OF ALS STOPPED MUSCLE WASTING AND SCARRING, SUGGESTING A NEW APPROACH TO TREAT THE DISEASE. DNA RECOMBINATION IN THE BRAIN LINKED TO ALZHEIMER'S DISEASE. JEROLD CHUN, M.D., PH.D., PUBLISHED BREAKTHROUGH RESEARCH DESCRIBING HOW GENE RECOMBINATION TAKES PLACE IN NORMAL BRAINS-BUT GOES AWRY IN ALZHEIMER'S DISEASE. GENE RECOMBINATION REQUIRES AN ENZYME CALLED REVERSE TRANSCRIPTASE, THE SAME TYPE OF ENZYME USED BY THE HIV VIRUS TO INFECT CELLS. THE FINDINGS PROVIDE SCIENTIFIC RATIONALE FOR CLINICALLY TESTING THE ANTIRETROVIRAL DRUGS THAT HAVE BEEN USED SAFELY FOR YEARS IN HIV PATIENTS AS AN ALZHEIMER'S THERAPY. CHILDREN'S HEALTH BOOSTING MUSCLE STEM CELLS TO TREAT MUSCULAR DYSTROPHY. LYING WITHIN OUR MUSCLES ARE STEM CELLS, INVISIBLE ENGINES THAT DRIVE THE TISSUE'S GROWTH AND REPAIR. ALESSANDRA SACCO, PH.D., UNCOVERED SPECIFIC CELL PROTEINS THAT REGULATE HOW MUSCLE STEM CELLS DECIDE WHETHER TO SELF-RENEW OR DIFFERENTIATE-AN INSIGHT THAT COULD LEAD TO MUSCLE-BOOSTING THERAPEUTICS FOR MUSCULAR DYSTROPHIES OR AGE-RELATED MUSCLE DECLINE. TRANSLATIONAL MEDICINE NEW STRATEGIC INITIATIVE WITH WARF THERAPEUTICS. THE INSTITUTE FORMALIZED A RESEARCH COLLABORATION AGREEMENT WITH WARF THERAPEUTICS-A PROGRAM OF THE WISCONSIN ALUMNI RESEARCH FOUNDATION ESTABLISHED IN 2018 TO TRANSLATE PROMISING BIOMEDICAL DISCOVERIES FROM THE UNIVERSITY OF WISCONSIN-MADISON INTO NOVEL MEDICINES. UNDER THE TERMS OF THE 5-YEAR AGREEMENT, WARF AND UW SCIENTISTS WILL WORK WITH THE PREBYS CENTER TO TRANSITION CLINICALLY RELEVANT TARGETS TO EARLY-STAGE DRUG DISCOVERY PROJECTS. ELI LILLY COLLABORATION ADVANCES TO PHASE 1 CLINICAL TRIAL. THE FIRST HEALTHY SUBJECT WAS DOSED IN A PHASE 1 CLINICAL TRIAL EVALUATING LY3361237, A BIOLOGIC THAT INHIBITS INFLAMMATION BY ACTIVATING AN IMMUNE CHECKPOINT RECEPTOR. THE SBP RESEARCH TEAM, LED BY CARL WARE, PH.D., PROVIDED DEEP FOUNDATIONAL SCIENTIFIC KNOWLEDGE FOR THE COMPOUND THAT MAY BENEFIT PATIENTS WITH IMMUNOLOGICAL DISORDERS SUCH AS LUPUS, PSORIASIS AND RHEUMATOID ARTHRITIS. THE COLLABORATION WITH ELI LILLY WAS FORMED IN 2015. MAYO CLINIC DRUG DISCOVERY COLLABORATION. THE COLLABORATION BETWEEN SBP AND THE MAYO CLINIC CONTINUES TO ADVANCE PROJECTS AIMED AT SPEEDING THE TRANSLATION OF SCIENTIFIC DISCOVERIES INTO POTENTIAL NEW DRUGS. BOTH INSTITUTIONS HAVE COLLABORATED ON MORE THAN 65 PROJECTS THAT HAVE GARNERED MORE THAN $11.3M IN GRANT FUNDING FROM NIH. THE COLLABORATION'S JOINT STEERING COMMITTEE LAST MET IN DECEMBER 2018 AND SELECTED THREE NEW PROJECTS - FOCUSED ON ALZHEIMER'S DISEASE, BREAST CANCER AND POLYCYSTIC KIDNEY DISEASE - TO ADD TO ITS GROWING PORTFOLIO. MAYO CLINIC INVESTIGATORS WILL PARTNER WITH THE PREBYS CENTER TO JOINTLY DEVELOP PRELIMINARY DATA PACKAGES SUITABLE FOR COMPETITIVE NIH DRUG DISCOVERY GRANT APPLICATIONS. SAN DIEGO ALZHEIMER'S COLLABORATION4CURE (C4C) INITIATIVE. ALZHEIMER'S SAN DIEGO, MRS. DARLENE SHILEY, COUNTY SUPERVISOR DIANE JACOB AND MAYOR KEVIN FAULCONER ALL REAFFIRMED THEIR COMMITMENT TO THE C4C INITIATIVE (TO FUND LOCAL ALZHEIMER'S DRUG DISCOVERY RESEARCH) BY PLEDGING ADDITIONAL FUNDING FOR A 4TH ROUND OF PROPOSALS. SBP'S PREBYS CENTER HAS BEEN INVOLVED SINCE ITS INCEPTION AND HAS BEEN PROUD TO SERVE AS THE DESIGNATED DRUG DISCOVERY CENTER FOR AWARDED PROPOSALS. IN OCTOBER 2018, THE PREBYS CENTER TEAM SHARED THAT THEY HAVE IDENTIFIED AN INHIBITOR THAT BINDS TO A MUTANT FORM OF THE PROTEIN TREM-2. TREM-2 IS THOUGHT TO PLAY A PROTECTIVE ROLE AGAINST ALZHEIMER'S DISEASE AND MUTATIONS IN TREM-2 INCREASE THE RISK OF ALZHEIMER'S DISEASE. THIS RESEARCH IS FUNDED BY A $1.3M GRANT FROM NIH. ELIMINATING HIV ONCE AND FOR ALL. ANTIRETROVIRAL THERAPIES HAVE MADE IT POSSIBLE FOR PEOPLE TO LIVE WITH HIV FOR DECADES. HOWEVER, SMALL RESERVOIRS OF HIV LIVE IN CELLS, LYING DORMANT AND GOING UNDETECTED BY THE IMMUNE SYSTEM. IF RETROVIRAL THERAPY IS DISCONTINUED, THE VIRUS REAWAKENS TO PRODUCE MORE VIRUSES AND INFECT CELLS. WITH SUPPORT FROM THE INSTITUTE'S TRANSLATIONAL SCIENCE INITIATIVE, THE LABORATORY OF SUMIT CHANDA, PH.D. WILL BE WORKING TO ADVANCE A COMPOUND DESIGNED TO REACTIVATE LATENT HIV-INFECTED CELLS SO THEY CAN BE KILLED OFF ONCE AND FOR ALL-A "SHOCK AND KILL" STRATEGY. FUNDING WILL SUPPORT STUDIES OF THE COMPOUND IN AN IN VIVO NON-HUMAN PRIMATE MODEL OF HIV LATENCY. SBP TECHNOLOGY ADVANCES TO PHASE 1 CLINICAL TRIAL. ANTI-CANCER TECHNOLOGY DEVELOPED IN THE LAB OF ERKKI RUOSLAHTI, M.D., PH.D., ADVANCED TO A PHASE 1 CLINICAL TRIAL FOR PANCREATIC CANCER. THE TECHNOLOGY HAS BEEN USED TO CREATE CEND-1, A COMPOUND DESIGNED TO IMPROVE THE EFFICACY OF ANTI-CANCER DRUGS. CEND-1 IS CO-ADMINISTERED WITH ANTI-CANCER DRUGS TO ENHANCE THEIR TUMOR PENETRATION, THEREBY IMPROVING EFFICACY OF THE THERAPY AND MINIMIZING TOXICITY. CEND-1 IS EXCLUSIVELY LICENSED TO DRUGCENDR, INC. COLLABORATING WITH USC. SBP'S PREBYS CENTER FINALIZED A RESEARCH COLLABORATION AGREEMENT WITH DR. JOHN CARPTEN OF USC. THE WORK FOCUSES ON COMPLETING A HIGH-THROUGHPUT SCREEN OF SBP'S CHEMICAL LIBRARIES IN SEARCH OF PROTOTYPE CHEMICALS, WHICH COULD BE DEVELOPED INTO TREATMENTS FOR BREAST CANCER. PROGRESS TOWARD NEW CANCER THERAPEUTICS. SBP'S PREBYS CENTER PRESENTED AT THE NCI CHEMICAL BIOLOGY CONSORTIUM (CBC) STEERING COMMITTEE MEETING TO REPORT ON THE RAPID PROGRESS OF TWO SBP-ORIGINATED PROJECTS ON EMERGENT CANCER TARGETS. THE PROJECTS, LED BY JORGE MOSCAT, PH.D. AND MARIA DIAZ-MECO, PH.D., AND NICHOLAS COSFORD, PH.D. AND LUTZ TAUTZ, PH.D., HAVE SO FAR GARNERED $2.5M IN FUNDING FROM CBC. BOTH PROJECTS EMPLOY KEY HIGH-THROUGHPUT SCREENING TECHNOLOGY THAT THE PREBYS CENTER HAS PARTICULAR EXPERTISE WITH AND THAT ENABLED THE IDENTIFICATION OF NOVEL COMPOUNDS WITH DISTINCT IMPROVEMENTS OVER CURRENT COMPETITOR COMPOUNDS. FORM 990, PART VI, LINE 11B PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW FORM 990 THE 990 IS PREPARED BY THE FINANCE DEPARTMENT. IT IS REVIEWED BY THE INSTITUTE'S TAX ADVISORS, SELECTED MEMBERS OF MANAGEMENT INCLUDING THE CFO AND AUDIT COMMITTEE AND PROVIDED TO MEMBERS OF THE BOARD PRIOR TO FILING. FORM 990, PART VI, LINE 12C DESCR OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICT OF INTEREST CONFLICT OF INTEREST STATEMENTS ARE GIVEN TO MANAGEMENT STAFF AND PRINCIPAL INVESTIGATORS ON A PERIODIC BASIS TO REPORT ON CONFLICTS OR LACK OF CONFLICTS. THE STATEMENTS ARE REVIEWED ANNUALLY BY THE SENIOR DIRECTOR, INTELLECTUAL PROPERTY AND THE SENIOR DIRECTOR, SPONSORED RESEARCH, WITH A SUMMARY OF THE REVIEW PROVIDED TO THE CFO. AN ASSESSMENT IS MADE AS TO WHETHER A CONFLICT CAN BE MANAGED BY THE EXISTING DEPARTMENTS AND PRACTICES. CONFLICTS ARE BROUGHT TO THE BOARD OF TRUSTEES ON AN AS NEEDED BASIS. CONFLICTS AND POTENTIAL CONFLICTS THAT INVOLVE THE CEO OR THE PRESIDENT ARE BROUGHT TO THE BOARD OF TRUSTEES TO ADDRESS ANY ACTUAL OR POTENTIAL POSSIBILITY THAT THE DESIGNATED REVIEWERS (I.E., SENIOR DIRECTOR, INTELLECTUAL PROPERTY AND THE SENIOR DIRECTOR, SPONSORED RESEARCH, AND THE CFO) COULD BE PRESSURED TO MAKE BIASED DECISIONS IN MANAGING CONFLICTS INVOLVING THE CEO OR PRESIDENT. AS TO RESTRICTIONS IMPOSED: THE INSTITUTE WILL EMPLOY THE MECHANISM THAT IS THE BEST FIT WITH THE FACTS AND CIRCUMSTANCES OF ANY IDENTIFIED CONFLICT OF INTEREST. METHODS TO MANAGE POTENTIAL CONFLICTS/ENFORCEMENT MECHANISM: REVIEWING MANAGEMENT IS RESPONSIBLE FOR MANAGING, REDUCING, OR ELIMINATING REAL OR POTENTIAL CONFLICTS OF INTEREST. EXAMPLES OF CONDITIONS OR RESTRICTIONS THAT MIGHT BE IMPOSED TO MANAGE, REDUCE, OR ELIMINATE CONFLICTS OF INTERESTS INCLUDE: -PUBLIC DISCLOSURE OF SIGNIFICANT FINANCIAL INTERESTS -MONITORING OF RESEARCH BY INDEPENDENT REVIEWERS -MODIFICATION OF THE RESEARCH PLAN -DISQUALIFICATION FROM PARTICIPATION IN THE PORTION OF FUNDED RESEARCH THAT COULD BE AFFECTED BY SIGNIFICANT FINANCIAL INTEREST -DIVESTITURE OF SIGNIFICANT FINANCIAL INTERESTS -SEVERANCE OF RELATIONSHIPS THAT CREATE ACTUAL OR POTENTIAL CONFLICTS -REVIEW OF COMMERCIAL SPONSORED RESEARCH AGREEMENTS FOR SCIENTIFIC MERIT BY THE PROGRAM PLANNING COMMITTEE -REMOVAL OF AN AFFECTED PARTY FROM NEGOTIATION WITH A COMPANY WITH WHICH HE/SHE HAS SIGNIFICANT FINANCIAL INTEREST. FORM 990, PART VI, LINES 15A & 15B PROCESS FOR DETERMINING COMPENSATION COMPENSATION FOR THE CEO, THE PRESIDENT, CHIEF FINANCIAL OFFICER, AND OTHER KEY EMPLOYEES IS ESTABLISHED ACCORDING TO INSTITUTE POLICIES WHICH ARE DESIGNED TO MEET THE IRS STANDARD FOR "REBUTTABLE PRESUMPTION OF REASONABLENESS". THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES, CONSISTING OF FOUR INDEPENDENT TRUSTEES, REVIEWS COMPARABILITY DATA PROVIDED BY AN INDEPENDENT EXTERNAL CONSULTANT THAT INCORPORATES AND EVALUATES INSTITUTE DATA AND THAT OF COMPARABLE ORGANIZATIONS AND MARKETS FROM WHICH THE INSTITUTE DRAWS ITS EXECUTIVE TALENT. UTILIZING THIS INFORMATION, THE COMPENSATION COMMITTEE, WHICH TYPICALLY SEEKS TO ESTABLISH COMPENSATION BETWEEN THE 50TH AND THE 75TH PERCENTILE OF THE COMPARABILITY DATA, MAKES A DETERMINATION WHETHER THE PROPOSED COMPENSATION IS REASONABLE. THE COMPENSATION COMMITTEE HAS BEEN DELEGATED AUTHORITY BY THE BOARD OF TRUSTEES TO REVIEW AND APPROVE COMPENSATION OF ALL POSITIONS EXCEPT FOR THE CEO. THE CEOS COMPENSATION PACKAGE IS REVIEWED AND APPROVED INITIALLY BY THE COMPENSATION COMMITTEE AND THEN GOES TO THE EXECUTIVE COMMITTEE FOR FINAL APPROVAL. THE COMPENSATION COMMITTEE CONTEMPORANEOUSLY AND ADEQUATELY DOCUMENTS THE BASIS FOR ITS DETERMINATION AND RECOMMENDATION TO THE EXECUTIVE COMMITTEE. IF APPROVED BY THE EXECUTIVE COMMITTEE, THE CEO COMPENSATION PACKAGE IS THEN IMPLEMENTED AND SUCH DOCUMENTATION IS KEPT IN THE WRITTEN AND ELECTRONIC RECORDS OF THE BOARD OF TRUSTEES. THE PROCESS WAS LAST COMPLETED ON JUNE 6, 2018 FOR THE FOLLOWING POSITIONS: 1) PRESIDENT 2) CFO 3) VP BUSINESS DEVELOPMENT 4) VP PHILANTHROPY 5) SVP DRUG DISCOVERY & DEVELOPMENT 6) CANCER CENTER DIRECTOR/PROFESSOR 7) INFECTIOUS & INFLAMMATORY DISEASE CENTER DIRECTOR/PROFESSOR FORM 990, PART VI, LINE 19 PROCESS FOR MAKING DOCUMENTS AVAILABLE TO THE PUBLIC DOCUMENTS ARE AVAILABLE UPON REQUEST. FL MED DISCOVERY INSTITUTE AT LAKE NONA 10901 N TORREY PINES ROAD LA JOLLA CA 92037 474997825 RESEARCH CA 501(c)(3) 7 SBPMDI true false false false false false false false false false false false false false false false false false false